CD274 and non-small cell lung carcinoma: Advanced NSCLC has been one of the first pioneers in becoming a common therapeutic focus for therapies targeting programmed death-1 (PD-1) or its ligand programmed death-ligand 1 (PD-L1) [4, 5].